Last reviewed · How we verify
NCT05671393
the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma
trial in Gastric Neuroendocrine Carcinoma in 801 participants. Completed in 15 December 2022.
1 December 2016
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 801 |
| Start date | 1 January 2008 |
| Primary completion | 1 December 2016 |
| Estimated completion | 15 December 2022 |
| Sites | 1 location across China |
Conditions studied
- Gastric Neuroendocrine Carcinoma — all drugs for Gastric Neuroendocrine Carcinoma →
Sponsor
Fujian Medical University
Who can join
Eligibility, any sex, with Gastric Neuroendocrine Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Due to lacking of evidence on surveillance for gastric neuroendocrine carcinoma (G-NEC), this study aimed to determine the optimal postsurgical surveillance strategy for G-NEC patients and compare its cost-effectiveness with traditional surveillance strategies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study.
Xu BB, He XY, Zhou YB, He QL, et al · · 2023 · cited 4× · PMID 37076132 · DOI 10.1097/js9.0000000000000401
Verify or expand the search:
- PubMed search for NCT05671393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Neuroendocrine Carcinoma
Currently open trials in the same condition.
- NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
- NCT02595424 — Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Sm · Phase 2 · active not recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05671393 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 4 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05671393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing